JP2021534188A5 - - Google Patents
Info
- Publication number
- JP2021534188A5 JP2021534188A5 JP2021507982A JP2021507982A JP2021534188A5 JP 2021534188 A5 JP2021534188 A5 JP 2021534188A5 JP 2021507982 A JP2021507982 A JP 2021507982A JP 2021507982 A JP2021507982 A JP 2021507982A JP 2021534188 A5 JP2021534188 A5 JP 2021534188A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- cancer
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719189P | 2018-08-17 | 2018-08-17 | |
| US62/719,189 | 2018-08-17 | ||
| US201862733380P | 2018-09-19 | 2018-09-19 | |
| US62/733,380 | 2018-09-19 | ||
| US201962808376P | 2019-02-21 | 2019-02-21 | |
| US62/808,376 | 2019-02-21 | ||
| US201962854701P | 2019-05-30 | 2019-05-30 | |
| US62/854,701 | 2019-05-30 | ||
| PCT/US2019/046852 WO2020037225A1 (en) | 2018-08-17 | 2019-08-16 | Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534188A JP2021534188A (ja) | 2021-12-09 |
| JP2021534188A5 true JP2021534188A5 (cg-RX-API-DMAC7.html) | 2022-08-15 |
Family
ID=67841175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507982A Ceased JP2021534188A (ja) | 2018-08-17 | 2019-08-16 | NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11407825B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3836972A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021534188A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210049122A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113194999A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019320818A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021002747A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3109790A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL280867A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021001924A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202035452A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020037225A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| JP2021534188A (ja) * | 2018-08-17 | 2021-12-09 | メルサナ セラピューティクス インコーポレイテッド | NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| TW202308649A (zh) * | 2021-05-03 | 2023-03-01 | 美商梅爾莎納醫療公司 | 用於治療卵巢癌之卡鉑與靶向NaPi2b之抗體聚合物-藥物共軛體的組合療法 |
| US20230338569A1 (en) * | 2021-09-09 | 2023-10-26 | Mersana Therapeutics, Inc. | NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER |
| KR20250089528A (ko) * | 2022-10-18 | 2025-06-18 | 투불리스 게엠베하 | 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도 |
| CN122122183A (zh) * | 2023-10-19 | 2026-05-29 | 酵活英属哥伦比亚有限公司 | 抗napi2b抗体-药物缀合物和使用方法 |
| KR102764613B1 (ko) | 2024-03-28 | 2025-02-12 | 한양대학교 에리카산학협력단 | NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3900534A1 (de) | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
| CH694588A5 (de) | 1999-02-09 | 2005-04-15 | Hoffmann La Roche | Menschliche intestinale Npt2B. |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| AU2003219665A1 (en) | 2002-01-15 | 2003-07-30 | Board Of Regents, The University Of Texas System | Napi type iib polypeptides and methods for making and using same |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| EP2076286B1 (en) | 2006-10-25 | 2016-03-09 | Wisconsin Alumni Research Foundation | Methods of reducing phosphate absorption using an anti-npt2b antibody |
| EP2250201B1 (en) | 2008-01-29 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| EP2240495B1 (en) | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| AU2009270988A1 (en) | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| JP5370826B2 (ja) | 2009-04-20 | 2013-12-18 | 株式会社パソロジー研究所 | 癌の組織型を判別するカクテル抗体、判別キット及び判別方法 |
| TWI507524B (zh) | 2009-11-30 | 2015-11-11 | 建南德克公司 | 診斷及治療腫瘤之組合物及方法 |
| EP2590965B1 (en) | 2010-07-07 | 2016-04-20 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| JP5827328B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス,インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| JP5827326B2 (ja) | 2010-07-07 | 2015-12-02 | アーデリクス,インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| EP2717916B1 (en) | 2011-06-10 | 2017-03-08 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2927022C (en) | 2013-10-11 | 2018-08-21 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| WO2015054659A1 (en) * | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9808528B2 (en) * | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| CA2969689A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| WO2017068097A1 (en) | 2015-10-23 | 2017-04-27 | Roche Diagnostics Gmbh | Methods of identifying an individual as to be treated by chemotherapy based on marker molecules and related uses |
| US10287259B2 (en) | 2016-03-14 | 2019-05-14 | The Penn State Research Foundation | Selenazolidine and thiazolidine compounds for treating cancer and other diseases |
| BR112018068461A2 (pt) * | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| US10772971B2 (en) | 2017-06-22 | 2020-09-15 | Mersana Therpeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
| EP3685166A2 (en) | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| JP2021534188A (ja) * | 2018-08-17 | 2021-12-09 | メルサナ セラピューティクス インコーポレイテッド | NaPi2bに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法 |
-
2019
- 2019-08-16 JP JP2021507982A patent/JP2021534188A/ja not_active Ceased
- 2019-08-16 WO PCT/US2019/046852 patent/WO2020037225A1/en not_active Ceased
- 2019-08-16 AU AU2019320818A patent/AU2019320818A1/en not_active Abandoned
- 2019-08-16 CN CN201980068682.0A patent/CN113194999A/zh active Pending
- 2019-08-16 US US16/542,642 patent/US11407825B2/en active Active
- 2019-08-16 KR KR1020217008012A patent/KR20210049122A/ko not_active Abandoned
- 2019-08-16 CA CA3109790A patent/CA3109790A1/en active Pending
- 2019-08-16 EP EP19762538.7A patent/EP3836972A1/en not_active Withdrawn
- 2019-08-16 BR BR112021002747-5A patent/BR112021002747A2/pt not_active IP Right Cessation
- 2019-08-16 MX MX2021001924A patent/MX2021001924A/es unknown
- 2019-08-16 TW TW108129249A patent/TW202035452A/zh unknown
-
2021
- 2021-02-15 IL IL280867A patent/IL280867A/en unknown
-
2022
- 2022-06-28 US US17/851,618 patent/US20220332815A1/en not_active Abandoned